Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it will not pursue capital raising activities in the immediate future.
This decision follows the recent discovery of immune biomarkers in patients with non-active secondary progressive multiple sclerosis treated with nasal foralumab.
The company said it remains focused on advancing its innovative therapies and delivering shareholder value.